Compare ACMR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | ICUI |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 2017 | 1995 |
| Metric | ACMR | ICUI |
|---|---|---|
| Price | $40.10 | $124.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $50.00 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 1.1M | 230.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | ★ 1.37 | 0.03 |
| Revenue | $74,643,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $29.37 | N/A |
| Revenue Next Year | $23.16 | $4.46 |
| P/E Ratio | ★ $30.08 | $4,255.33 |
| Revenue Growth | ★ 104.47 | N/A |
| 52 Week Low | $16.82 | $107.02 |
| 52 Week High | $71.65 | $160.29 |
| Indicator | ACMR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 35.07 |
| Support Level | $36.61 | $122.17 |
| Resistance Level | $42.32 | $125.00 |
| Average True Range (ATR) | 2.40 | 4.96 |
| MACD | -0.46 | 0.12 |
| Stochastic Oscillator | 1.19 | 3.29 |
ACM Research Inc supplies advanced, innovative capital equipment developed for the world-wide semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.